Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system

BACKGROUND: The recent introduction of direct acting antivirals for the treatment of hepatitis C virus (HCV) has dramatically improved treatment options for HCV infected patients. However, in the United States (US) treatment uptake has been low and time to initiation of therapy has been long. We sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Javanbakht, Marjan, Archer, Roxanne, Klausner, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641373/
https://www.ncbi.nlm.nih.gov/pubmed/33147293
http://dx.doi.org/10.1371/journal.pone.0241615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641373/
https://www.ncbi.nlm.nih.gov/pubmed/33147293
http://dx.doi.org/10.1371/journal.pone.0241615

Ejemplares similares